Physicians Administrative Solutions LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$732,452	87
2024	Research	$1,027,465	247
2023	Research	$153,419	9
2022	Research	$1,300,903	26
2021	Research	$867,023	20
2020	Research	$228,805	9

Breakdown

Who paid Research payments · program years 2020–2025

Sanofi Pasteur Inc. $3,864,050 141 payments
Sanofi US Services Inc. $269,270 230 payments
GlaxoSmithKline, LLC. $176,747 27 payments

Studies the money was for Research payments · program years 2020–2025

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $1,461,942 277 payments
Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants $1,085,950 12 payments
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). $735,383 10 payments
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers $275,010 26 payments
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants. $210,901 3 payments
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) $192,002 21 payments
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $86,312 12 payments
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers $76,787 9 payments
A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $74,445 7 payments
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $44,677 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.